论文部分内容阅读
目的:探讨使用曲美他嗪对缺血性心脏病并发心力衰竭患者进行治疗的效果。方法:选取近期我院收治的80例缺血性心脏病并发心力衰竭的患者作为研究对象。随机将这些患者分为对照组和观察组,每组各40例患者。为对照组患者进行常规治疗,为观察组患者在进行常规治疗的基础上使用曲美他嗪进行治疗。然后观察两组患者治疗的效果及不良反应的发生情况。结果:经治疗,观察组患者治疗的总有效率及不良反应的发生率均明显优于对照组患者,差异具有统计学意义(P<0.05)。结论:使用曲美他嗪对缺血性心脏病合并心力衰竭的患者进行治疗的效果显著,安全性较高,值得在临床上推广应用。
Objective: To investigate the effect of trimetazidine on patients with ischemic heart disease complicated with heart failure. Methods: A total of 80 patients with ischemic heart disease complicated with heart failure treated in our hospital were selected as the research object. These patients were randomly divided into control group and observation group, each group of 40 patients. Patients in the control group were treated routinely with trimetazidine for the treatment of patients in the observation group on the basis of routine treatment. Then observe the effect of two groups of patients and the incidence of adverse reactions. Results: After treatment, the total effective rate of treatment and the incidence of adverse reactions in the observation group were significantly better than those in the control group, the difference was statistically significant (P <0.05). Conclusion: The effect of trimetazidine on patients with ischemic heart disease and heart failure is significant and safe. It is worth to be popularized clinically.